Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

CRISPR-Modified Cells Have Been Used in a Person for the First Time

A clinical trial in China aims to see if engineered immune cells can fight off late-stage lung cancer.

A team of Chinese scientists has become the first to test CRISPR gene-edited cells in a human. The researchers, from Sichuan University in Chengdu, injected the cells into a patient with advanced lung cancer.

The experiment marks the beginning of an early stage clinical trial designed to test the safety of using CRISPR—a cheap, easy, and reasonably accurate way to edit DNA in living cells—to disable a gene in T-cells that suppresses immune response. According to Nature, which first broke the news of the trial, the injection went “smoothly,” and 10 patients are expected to receive injections.

Genetically modifying immune cells to turn them into cancer-hunters is a technology that’s now a few years old. Treatments remain experimental, though, and because their side effects can be fatal, messing with a patient’s immune system on the genetic level is only done for the sickest patients suffering from a limited subset of cancers.

T-cells surround a cancer cell.

But those techniques—in which immune cells are harvested from a patient, modified, and then returned to their body—involve adding a gene to give the cells a receptor that turns them into cancer-killers. Using CRISPR allowed the researchers to turn off a gene that codes for the PD-1 protein, which prevents the immune system from attacking cancer.

Human trials of CRISPR have been proposed in the U.S., including a scheme to knock out the gene behind PD-1—but so far none have been carried out.

Carl June, a researcher from the University of Pennsylvania who hopes to carry out some of the first such experiments in America, told Nature that he thinks  the news could “trigger ‘Sputnik 2.0,’ a biomedical duel on progress between China and the United States.”

(Read more: Nature, “First Human Test of CRISPR Proposed,” “10 Breakthrough Technologies 2016: Immune Engineering”)

Technology is changing faster than ever before.
At EmTech MIT, hear experts’ opinions on the future of their industries.

Learn more and register
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.